WILMINGTON, Delaware, Feb. 21 -- AstraZeneca, a biopharmaceutical company, issued the following news release: * * * CALQUENCE(R) plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with 77% of patients progression free at three years in AM more PR

SYDNEY, Australia, Feb. 21 (TNSjou) -- The University of New South Wales posted the following news: * * * Study confirms overlooked cause of gastro illness circulating locally Tom Melville The source of an emerging gastro-causing bacterium remains unknown, and UNSW researchers say better testing could help provide answers. Most bacterial gastrointestinal illnesses in Australia are thought to be caused by two pathogens, Campylobacter and Salmonella. But an emerging pathogen, Aeromonas, is m more PR